Pharmaceuticals
Bridge Biotherapeutics to Present Updated Preclinical Data of BBT-207 at the AACR 2023 Annual Meeting
* The abstract of BBT-207 preclinical studies is now available on the AACR
website
2023-03-15 21:00
2690
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program
* Applications for physicians trained in Indonesia now open until April 15, 2023 12:00 AM * The Pharmaceutical Industry Fellowship Program provides physicians with the opportunity to experience the various steps of the drug development process ROCKVILLE, Md. and SEOUL, South Korea, March 15, ...
2023-03-15 19:00
2499
Nippon Express (Belgium) Joins Pharma.Aero
TOKYO, March 15, 2023 /PRNewswire/ -- Nippon Express (Belgium) N.V./S.A. (hereinafter "NX Belgium"), a group company of NIPPON EXPRESS HOLDINGS, INC., became the first Japanese forwarder to join Pharma.Aero (*) onJanuary 25 this year. Pharma.Aero logo: https://kyodonewsprwire.jp/img/202303033576...
2023-03-15 14:00
1997
Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting
BEIJING and SHANGHAI and BOSTON, Mass., March 14, 2023 /PRNewswire/ -- Jacobin Pharma (1167.HK) today announced that the company will present the results of three preclinical studies of KRASmulti inhibitor JAB-23425, CD73-STING iADC JAB-X1800, and Aurora kinase A inhibitor JAB-2485 in form of the...
2023-03-15 10:45
3612
Ascentage Pharma to Present Latest Results from Three Preclinical Studies at 2023 American Association for Cancer Research Annual Meeting
SUZHOU, China and ROCKVILLE, Md., March 14, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the latest results from three preclinical s...
2023-03-15 07:59
3437
Mabwell Launched First in human Clinical Trial of Its Iron Homeostasis Regulating Macromolecular Drug 9MW3011
SHANGHAI, March 14, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, launched first in human clinical trial of its iron homeostasis regulating macromolecular drug 9MW3011. The study (CTR20230046) is a phase 1, single cente...
2023-03-14 23:42
2818
Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneous T-cell Lymphoma
NANJING, China, March 14, 2023 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), an innovative global biopharmaceutical company, announced today that Simcere Zaiming, an innovative oncology pharmaceutical company of Simcere has entered into a clinical collaboration agreeme...
2023-03-14 20:00
3239
Patient Enrollment Completed for Phase III Clinical Trial of Akeso's Cadonilimab in Treatment of Gastric Cancer
HONG KONG, March 14, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that patient enrollment has been completed for its pivotal Phase III clinical trial for cadonilimab (PD-1/CTLA-4 bi-specific antibody, AK104), the world's first approved and marketed dual-immune checkpoint bi-specific antib...
2023-03-14 17:01
2078
AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease
TAIPEI, March 10, 2023 /PRNewswire/ -- AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the development and commercialization of AJ201 in the U.S.,Canada, European Union, Great Britain, and Israel for spinal ...
2023-03-10 19:00
2128
Allorion Therapeutics, a next-generation precision medicine company focusing on oncology and autoimmune diseases, raises $50 million Series B financing
BOSTON, March 9, 2023 /PRNewswire/ -- Allorion Therapeutics ("Allorion"), a biotech company focusing on next-generation precision medicine for oncology and autoimmune diseases, announces the completion of a$50 million Series B financing round, co-led by INCE Capital and Qiming Venture Partners, w...
2023-03-10 09:00
2586
GenFleet Therapeutics to Present Phase I Data for GFH312 at 2023 American Society for Clinical Pharmacology & Therapeutics Meeting
SHANGHAI, March 9, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the results from phase I study of GFH312 (RIPK1 inhibitor) monotherapy will be presented as a poster at the 2023 ASC...
2023-03-09 19:00
2012
Estrella Biopharma Announces FDA Clearance of IND Application for Phase I/II Clinical Trial (Starlight-1) of EB103, a CD19-Targeted ARTEMIS® T Cell Therapy, to Patients with B-Cell Lymphomas
Initiation of Phase I/II Clinical Trial (Starlight-1) Expected to Occur in Second Half of 2023 EMERYVILLE, Calif. and NEW YORK, March 8, 2023 /PRNewswire/ -- Estrella Biopharma, Inc. ("Estrella"), a biopharmaceutical company whose mission is to harness the evolutionary power of the human immune ...
2023-03-09 05:15
2310
Hovione receives the 2023 CDMO Leadership Award in all six categories and is Champion in Compatibility and Expertise
LISBON, Portugal, March 8, 2023 /PRNewswire/ -- Hovione, the leader in spray
drying and particle engineering, won the2023 CDMO Leadership Award
2023-03-08 22:00
2480
MSCI ESG Updated I-Mab to "A" Rating
GAITHERSBURG, MD. and SHANGHAI, March 7, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that I-Mab has been granted "A" rating by MSCI (Morgan ...
2023-03-07 21:02
2360
HanAll Biopharma's Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis
* The trial met its primary endpoint and key secondary endpoints, with a favorable safety profile * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China for the treatment of myasthenia gravis SEOUL, South Korea, March 6, 2023 /PRNewswire/ -- HanAll Biopharma...
2023-03-06 20:00
2295
Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Therapy
SUZHOU,China, March 2, 2023 /PRNewswire/ -- Porton Advanced Solutions Ltd.
(Porton Advanced) and DanausGT Biotechnology Co., Ltd. (DanausGT) announced on
February 27, 2023, a strategic collaboration in gene and cell therapy pipelines
to expedite the development of innovative therapeutics.
2023-03-02 20:00
2743
Sanyou Biopharmaceuticals opens Cambridge MA, US office, expanding its business outreach to a central hub of biotech network
CAMBRIDGE, Mass., March 2, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is opening a new office in Cambridge Innovation Centre, CIC, marking a new era towards the company's rising ambition on serving and collaborating with world's best biotech sta...
2023-03-02 18:00
1995
111 to Announce Fourth Quarter and Fiscal Year 2022 Unaudited Financial Results- Conference Call to Follow
SHANGHAI, March 2, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results...
2023-03-02 15:35
2953
GenFleet receives EMA approval for phase Ib/II study of GFH925 (KRAS G12C inhibitor) in combination with ERBITUX® (cetuximab) treating patients with advanced NSCLC in first-line setting
SHANGHAI, March 1, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced today that European Medicine Agency (EMA) approved the phase Ib/II study of GFH925 (KRASG12C inhibitor) in combination wit...
2023-03-01 19:00
2426
First in Class, Mabwell Announces the TGA Approval of 9MW3811 for IND
SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that its IND application of its self-developed 9MW3811 injection for tumor and pulmonary fibrosis has been approved by the Therapeutic Goods Admi...
2023-02-28 23:00
2357
Week's Top Stories
Most Reposted
Agoda Launches Free Global eSIMs for VIP Diamond Members
[Picked up by 322 media titles]
2026-02-10 14:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Rockwell Automation Strengthens Industrial Cybersecurity with New Security Operations Center in Singapore
[Picked up by 298 media titles]
2026-02-09 10:00
Blackpanda Japan Announces Strategic Partnership with SoftBank to Strengthen Cyber Incident Response in Japan
[Picked up by 298 media titles]
2026-02-10 13:31Carro unveils quirky generative AI ad campaign highlighting its 'Surprisingly Short' AI-enabled car-selling process
[Picked up by 296 media titles]
2026-02-11 11:00
Most Read
Rockwell Automation Strengthens Industrial Cybersecurity with New Security Operations Center in Singapore
2026-02-09 10:00
8329
AIA RESEARCH REVEALS INGRAINED HEALTH STEREOTYPES ARE HOLDING BACK WELLBEING IN ASIA
2026-02-09 16:08
6646
Aon and KNIAZHA VIENNA INSURANCE GROUP announce new $25M war-risk insurance facility with the U.S. International Development Finance Corporation
2026-02-09 22:42
6456
Agoda Launches Free Global eSIMs for VIP Diamond Members
2026-02-10 14:00
6020
